checkAd

     112  0 Kommentare Valbiotis Accelerates Its Marketing Strategy

    Regulatory News:

    Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, is accelerating its marketing strategy.

    Sébastien PELTIER, Chairman of the Valbiotis Board of Directors, states: "Today, we are embarking on a complementary development cycle to commercialize our innovative active substances, with the aim of providing breakthrough solutions for reducing the risk factors of cardio-metabolic diseases. Our new strategy aims to accelerate the growth of Valbiotis and to boost its capacity for innovation using two main levers: firstly, the signing of international partnerships (global or regional) with major players in the nutrition and healthcare sectors, supported by the specialist firm AEC Partners1, and secondly, the company's own marketing of its products on the French market. This dual strategy, creating value, will enable Valbiotis to rapidly target the global food supplement market, estimated at 250 billion euros in 2025, with annual growth of 9.6%, including 3.2 billion euros for France, with annual growth of 7.3%2. The exponential demand for natural, non-drug preventive products, market studies3 conducted with healthcare professionals and patients/consumers, combined with our recent positive Phase II clinical results for TOTUM•070, have led us to adapt our marketing strategy."

    Committed to preventing and fighting metabolic and cardiovascular diseases through the development of unique combinations of plant-based molecules since 2014, Valbiotis now has a portfolio of four active substances in late-stage development with TOTUM•63 in prediabetes, TOTUM•070 in LDL hypercholesterolemia ("bad cholesterol"), TOTUM•854 in the reduction of blood pressure, and TOTUM•448 in the management of metabolic liver disease (NAFL and NASH). This solid pipeline of four products with proven efficacy based on preclinical and clinical data is the result of eight years of sustained R&D activities. Today, Valbiotis is entering a new phase of its development focused on revenue generation and structuring the Company to give this product portfolio every chance of success on a global scale.

    Seite 1 von 4




    Business Wire (engl.)
    0 Follower
    Autor folgen

    Valbiotis Accelerates Its Marketing Strategy Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, is accelerating its marketing strategy. …